Johannes Antonie Bogaards, PhD, Amsterdam University Medical Center, The Netherlands
Dr J A (Hans) Bogaards is a senior associate in the Department of Epidemiology & Data Science at Amsterdam UMC. For more than 15 years he has studied the epidemiology of HPV-related diseases, ranging from the natural history of infection to viral dynamics after prophylactic vaccination and HPV-based screening for cervical cancer. He has worked at the National Institute for Public Health and has been part of several EU-funded consortia (CoheaHr, PreHdict, RISCC). His current research focuses on risk-based policies to efficiently manage the influx of HPV-vaccinated women into cervical cancer screening programs.
Julia Brotherton, B Med(Hons), MPH(Hons), Grad Dip App Epi, FAFPHM, PhD, The University of Melbourne, Australia
Dr Julia Brotherton is a public health physician, epidemiologist, and Professor of Cancer Prevention Policy and Implementation at the Melbourne School of Population and Global Health, University of Melbourne. She is also a Professorial Fellow at the National Centre for Immunization Research and Surveillance, Sydney, Australia. For over 15 years, Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination and cervical screening programs.
Ashish A Deshmukh, PhD, MPH, Medical University of South Carolina, USA
Dr Ashish A Deshmukh is an associate professor of public health sciences and co-leader of the Cancer Control Program at the Hollings Cancer Center of the Medical University of South Carolina. He is a cancer population scientist whose research on human papillomavirus infection and associated cancers lies at the intersection of cancer epidemiology, health economics, and decision science. Particularly, he focuses on quantifying infection and associated cancer risk and evolving epidemiology and guiding the development and implementation of risk-targeted, sustainable, and optimal (cost-effective) primary (HPV vaccination) and secondary (screening and follow-up) preventive interventions using data-driven disease (mathematical) simulation models. At MUSC and Hollings Cancer Center, he leads an active mentoring program in HPV and associated cancer epidemiology, decision science, and simulation modeling, having mentored over 20 graduate students, postdoctoral trainees, and junior faculty members.
Claire Nightingale, PhD, MSc, BSc(Hons), The University of Melbourne, Australia
Dr Claire Nightingale is an implementation researcher with two decades of experience in global health, health systems and evaluation. Claire has worked in Papua New Guinea, Cambodia, Myanmar, and Australia on programs aiming to improve access to new diagnostics and models of care that may improve access and health outcomes. Claire currently leads a program of work focused on improving equity in Australia’s cervical screening program.
Kalyani Sonawane, PhD, Medical University of South Carolina, USA
Dr Kalyani Sonawane’s research focuses on analyzing high-dimensional healthcare data to study cancer prevention and treatment strategies, and to evaluate their downstream impact on population health outcomes. Her primary interest is in examining the landscape of human papillomavirus (HPV) infection and HPV-associated cancer in the United States, particularly understanding the epidemiology of HPV-associated cancers, barriers to HPV vaccination, and the prevention and treatment of HPV-associated cancers among marginalized groups.
